Iovance Biotherapeutics Inc (IOVA)


Stock Price Forecast

Feb. 21, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Iovance Biotherapeutics Inc chart...

About the Company

Iovance Biotherapeutics aims to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers. Tumor infiltrating lymphocyte (TIL) therapy uses a patient's own immune cells to attack cancer. TIL cells are extracted from a patient's own tumor tissue, expanded through a proprietary process, and infused back into the patient. Upon infusion, TIL reach tumor tissue, where they attack cancer cells. The company has completed dosing in pivotal programs in patients with metastatic melanoma and cervical cancer. In addition, the company's TIL therapy is being investigated in a registration-supporting study for the treatment of patients with locally advanced, recurrent or metastatic non-small cell lung cancer. Clinical studies are also underway to evaluate TIL in earlier stage cancers in combination with currently approved treatments, and to investigate Iovance peripheral blood lymphocyte (PBL) T cell therapy for blood cancers.

Employees

241

CEO

Maria Fardis

Exchange

NASDAQ

Website

www.iovance.com

$M

Total Revenue

241

Employees

$2B

Market Capitalization

-4.50

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $IOVA News

Piper Sandler Maintains Overweight Rating for Iovance Biotherapeutics: Here's What You Need To Know

4d ago, source:

Piper Sandler has decided to maintain its Overweight rating of Iovance Biotherapeutics (NASDAQ:IOVA) and raise its price target from $18.00 to $19.00. Shares of Iovance Biotherapeutics are trading up ...

Iovance Biotherapeutics (NASDAQ: IOVA)

4d ago, source: The Motley Fool

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product ...

Q4 2023 Iovance Biotherapeutics Inc Earnings Call

19d ago, source: Yahoo Finance

Sara Pellegrino; Senior Vice President, Investor Relations and Corporate Communications; Iovance Biotherapeutics Inc Frederick Vogt; Interim President and Chief Executive Officer; Iovance ...

Iovance's (IOVA) Q4 Earnings & Sales Fall Short of Estimates

18d ago, source: Hosted on MSN

Iovance Biotherapeutics, Inc. IOVA incurred a loss of 45 cents per share in fourth-quarter 2023, wider than the Zacks Consensus Estimate of a loss of 44 cents.In the year-ago quarter, the company ...

Iovance Biotherapeutics to Present at Upcoming Conferences

17d ago, source: Nasdaq

Barclays 26th Annual Global Healthcare ConferenceFireside Chat: March 12, 2024 at 10:45 a.m. ETMiami, FL Amtagvi™ and its accompanying design marks, Proleukin®, Iovance®, and IovanceCares ...

Iovance Biotherapeutics files patent for treatment of double-refractory metastatic melanoma using tils

6d ago, source: Pharmaceutical Technology

Discover how Iovance Biotherapeutics is revolutionizing melanoma treatment with patented TIL therapy for double-refractory cases.

Iovance Biotherapeutics, Inc. (IOVA) Q4 2023 Earnings Call Transcript

19d ago, source: Seeking Alpha

Welcome to the Iovance Biotherapeutics Conference Call to discuss the Full Year 2023 Results and recent Corporate Updates. My name is Kevin, and I'll be your operator for today's call. At this ...

Iovance Biotherapeutics Inc IOVA

6d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q4 2023 Earnings Call Transcript

19d ago, source: Yahoo Finance

Iovance Biotherapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to […] ...

Iovance Biotherapeutics Inc IOVA

7d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...